Hannah Nealey
Psychiatric/Mental Health · Fuquay Varina, NCNPI 1649793167
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,355 of the $75,287 with a category attached, or 76.2%. AbbVie accounts for 88.0% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2023 at $31,106 and has fallen 79.4% since, to $6,398 in 2025. Among psychiatric/mental health clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 738 payments — averaging $102.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$66K
- Corium, LLC$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Takeda Pharmaceuticals U.S.A., Inc.$623
- Otsuka America Pharmaceutical, Inc.$561
- Johnson & Johnson$542
- plus $5K from 26 others
What the payments were for
- Consulting fees$1730%
- Speaking & faculty fees$57,35576%
- Travel & lodging$6,0188%
- Food & beverage$11,72916%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 288 | $66,236 |
| Corium, LLC | 29 | $1,589 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 89 | $1,054 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $623 |
| Otsuka America Pharmaceutical, Inc. | 35 | $561 |
| Johnson & Johnson | 25 | $542 |
| Alkermes, Inc. | 26 | $534 |
| Neurocrine Biosciences, Inc. | 26 | $456 |
| Teva Pharmaceuticals USA, Inc. | 25 | $441 |
| Lundbeck LLC | 23 | $434 |
| Bausch Health US, LLC | 17 | $343 |
| Axsome Therapeutics, Inc. | 10 | $299 |
| Vanda Pharmaceuticals Inc. | 15 | $295 |
| Sunovion Pharmaceuticals Inc. | 16 | $240 |
| Neuronetics, Inc. | 2 | $229 |
| Supernus Pharmaceuticals, Inc. | 9 | $220 |
| Idorsia Pharmaceuticals US Inc | 8 | $153 |
| Ironshore Pharmaceuticals Inc. | 6 | $142 |
| Tris Pharma Inc | 8 | $128 |
| Validus Pharmaceuticals LLC | 2 | $117 |
| Eisai Inc. | 6 | $93 |
| Adlon Therapeutics L.p. | 5 | $85 |
| Merck | 5 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Almatica Pharma LLC | 4 | $62 |
| Noven Therapeutics, LLC | 3 | $53 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Indivior Inc. | 3 | $47 |
| Neos Therapeutics, LP | 3 | $47 |
| Novo Nordisk | 2 | $30 |
| Alfasigma USA, Inc. | 1 | $24 |
| USWM, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$62,503
- Azstarys$1,102
- NEUROSTAR TMS THERAPY$215
- Auvelity$113
- Equetro$101
How this compares
$75,287 in reported general payments places this provider in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atomoxetine Hcl | 20 | $557 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $275 |
| Quetiapine Fumarate | 15 | $139 |
| Alprazolam | 17 | $79 |
| Lorazepam | 16 | $55 |
| Lamotrigine | 23 | $39 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Fuquay Varina
- Adriane DehghanFuquay Varina$11K
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Clarence RunnelsCreedmoor$339K
- Lisa SuddrethGastonia$111K
- April NandigamGreensboro$88K
- Jessica StoneRocky Mount$63K
- Deborah GranickRaleigh$28K
- Ronald PattersonFayetteville$25K
- Ajay PatelRaleigh$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.